kinase inhibitor

p38 MAP Kinase Inhibitor Ⅵ is a potent p38 MAP Kinase inhibitor with anti-inflammatory activity.

Pim-1/2 Kinase Inhibitor 1, an orally active inhibitor, impedes the action of Pim kinases by preventing their ability to phosphorylate peptides. It particularly inhibits the phosphorylation of 4E-BP1 and p27 Kip1 by Pim protein kinases. This compound is valuable in cancer research, with a notable application in studying prostate cancer [1].

Protein kinase inhibitor 6 (PKI 6) is a compound that acts as an inhibitor of protein kinases.

RIP1 kinase inhibitor 1 is an orally available and brain-penetrating inhibitor of RIP1 kinase with pKi of 9.04.

RIP2 kinase inhibitor 1 is a potent and selective receptor interacting inhibitor of protein 2 (RIP2) kinase(RIP2 FP with an IC50 of 0.03 μM ),and is used for autoinflammatory disorders.

RIP2 kinase inhibitor 2 is a compound that inhibits receptor-interacting protein-2 kinase (RIP2).

TAO Kinase inhibitor 1 delays mitosis and induces mitotic cell death. TAO Kinase inhibitor 1 is a selective and ATP-competitive thousand-and-one amino acid kinases inhibitor (IC50s: 11 to 15 nM for TAOK1 and 2, respectively).

Tpl2 Kinase Inhibitor 1 is an effective and selective Tpl2 inhibitor.

Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.

Pim-1 kinase inhibitor 11 (10f) is an inhibitor of PIM-1 with an IC50 value of 0.18 μM. It exhibits anticancer activity by inducing apoptosis and causing cell cycle arrest.

Multi-target kinase inhibitor 3 (compound 6i) is a potent multi-target anticancer agent.

Protein Kinase Inhibitor 12 (compound 1-91) is a triazole derivative and protein kinase inhibitor, particularly effective against PIM-1, CDK-2, GSK-3, and SRC mammalian protein kinases, and can be used to study diseases related to protein kinases.

Aurora kinase inhibitor-13 (Compound 2) is an inhibitor of Aurora kinase, with an IC50 value of 2.3 μM for Aurora kinase A.

Protein kinase inhibitor 9 (Compound example 175) is an inhibitor of serine/threonine and tyrosine kinase activities. It can be utilized in research related to cancer, hyperproliferative diseases, rheumatoid arthritis, immune system disorders, transplant rejection, and inflammatory diseases.

Protein kinase inhibitor 11 (Compound I-96) is an agent that inhibits the activity of PIM-1, CDK-2, GSK-3, and SRC. It shows potential for research in cancer, autoimmune diseases, and neurodegenerative disorders.

p38 Kinase inhibitor 7 (Comp:XXXIX) is an inhibitor of p38α, with an IC50 value of 5.25 nM. It also effectively suppresses TNFα production in THP-1 cells, demonstrating an IC50 of 5.88 nM.

Protein kinase inhibitor 10 is a protein kinase inhibitor with IC50 values of 28.9 μM, 13.6 μM, and 2.41 μM for TAM receptors, FAK, and KIT, respectively. It can inhibit abnormal and excessive cell proliferation, showing potential for research in the field of cancer treatment.

Protein kinase inhibitor 14 (Compound 13) exhibits inhibitory effects on various serine/threonine kinases and receptor/non-receptor tyrosine kinases.

Protein kinase inhibitor 16 demonstrates inhibitory activity against various Ser/Thr kinases and receptor/non-receptor tyrosine kinases.

Protein kinase inhibitor 15 (Compound A.35.3) exhibits inhibitory activity against various Ser/Thr kinases and receptor/non-receptor tyrosine kinases.

p38 Kinase inhibitor 8 (Compound CCLXXVIII) is an orally active inhibitor targeting p38β and JNK2α2, with IC50 values of 6.3 nM and 53.6 nM, respectively. It has demonstrated anti-inflammatory effects in a rat model of collagen-induced arthritis.

Protein kinase inhibitor 13 (Compound I-90) functions as a kinase inhibitor, specifically targeting kinases such as PIM-1, CDK-2, GSK-3, and SRC.

PDGFRαkinase inhibitor 3 (Compound L7) is a potent inhibitor targeting the PDGFRαD842V kinase, exhibiting IC50 values of 23.8 nM in biochemical assays and 2.1 nM in cellular assays. It binds to the ATP binding site of PDGFRαD842V, blocking downstream signaling pathways and inhibiting kinase activity. PDGFRαkinase inhibitor 3 is applicable in gastrointestinal stromal tumor (GIST) research.

Multi-target kinase inhibitor 4 (Compound 2) is a PI3K/DNA-PK inhibitor and a potent chemosensitizer that enhances the number of DNA double-strand breaks induced by Doxorubicin. It serves as an effective multidrug resistance (MDR) inhibitor, demonstrating inhibitory activity against P-glycoprotein (P-gp) mediated drug efflux. Multi-target kinase inhibitor 4 can be encapsulated in PEG-coated lipid nanoparticles.